Drug Profile
Pretomanid - Global Alliance for TB Drug Development/Novartis
Alternative Names: Pa; PA 824Latest Information Update: 12 Apr 2023
Price :
$50
*
At a glance
- Originator Novartis
- Developer Global Alliance for TB Drug Development; Viatris Inc
- Class 2 ring heterocyclic compounds; Antituberculars; Nitroimidazoles; Oxazines; Phenyl ethers; Small molecules
- Mechanism of Action Cell wall inhibitors; Nitric oxide stimulants; Protein synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Registered Tuberculosis
Most Recent Events
- 19 Feb 2023 Efficacy and adverse events data from a phase III trial for Tuberculosis presented at the 30th Conference on Retroviruses and Opportunistic Infections 2023 (CROI-2023)
- 19 Feb 2023 Efficacy and adverse event from a phase II/III trial in Tuberculosis presented at the 30th Conference on Retroviruses and Opportunistic Infections (CROI-2023)
- 29 Nov 2022 Phase-II/III development in Tuberculosis (Combination Therapy, In adolescents, In the elderly, Treatment-resistant, In adults) is ongoing in Belarus (PO) (NCT02589782)